<DOC>
	<DOCNO>NCT02732210</DOCNO>
	<brief_summary>The objective study describe persistence Prolia® 60 mg administer subcutaneously ( SC ) every 6 month ( Q6M ) 12 24 month .</brief_summary>
	<brief_title>Persistence With Prolia® ( Denosumab ) Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description>The study multi-center , single-arm , prospective , non-interventional observational study postmenopausal woman osteoporosis treat Prolia® osteoporosis routine clinical practice .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Enrollment within 4 week follow administration first Prolia® ( denosumab 60 mg ) injection Received Prolia® subcutaneously treatment osteoporosis consistent local ( US/Canada ) product label Subject subject 's legally acceptable representative provide informed consent . Participation ongoing previous denosumab clinical trial Currently enrol another investigational device drug study , less 6 month since end another investigational device drug study ( ) , receive investigational agent ( ) Contraindicated treatment Prolia® accord approve applicable local product label ( US/Canada ) Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>